Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Tóm tắt
Từ khóa
Tài liệu tham khảo
Scholl, 2018, Drug and opioid-involved overdose deaths–United States, 2013-2017., MMWR Morb Mortal Wkly Rep, 67, 1419, 10.15585/mmwr.mm675152e1
Robinson, 2017, Brief report: nonfatal overdose events among persons who inject drugs: findings from seven national HIV behavioral surveillance cities 2009 & 2012., J Acquir Immune Defic Syndr, 75, S341, 10.1097/QAI.0000000000001426
Burnett, 2018, HIV infection and HIV-associated behaviors among persons who inject drugs—20 cities, United States, 2015., MMWR Morb Mortal Wkly Rep, 67, 23, 10.15585/mmwr.mm6701a5
Hsu, 2017, Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001-12., Addiction, 112, 1558, 10.1111/add.v112.9
Zibbell, 2018, Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014., Am J Public Health, 108, 175, 10.2105/AJPH.2017.304132
Cranston, 2019, Notes from the field: HIV diagnoses among persons who inject drugs–Northeastern Massachusetts, 2015-2018., MMWR Morb Mortal Wkly Rep, 68, 253, 10.15585/mmwr.mm6810a6
Weir, 2019, The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis., CMAJ, 191, E93, 10.1503/cmaj.180694
Chen, 2019, Prevention of prescription opioid misuse and projected overdose deaths in the United States., JAMA Netw Open, 2, 10.1001/jamanetworkopen.2018.7621
Ciccarone, 2019, The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis., Int J Drug Policy, 71, 183, 10.1016/j.drugpo.2019.01.010
Sordo, 2017, Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies., BMJ, 357, j1550, 10.1136/bmj.j1550
Clark, 2015, Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history., J Subst Abuse Treat, 57, 75, 10.1016/j.jsat.2015.05.001
Hser, 2016, Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial., Addiction, 111, 695, 10.1111/add.v111.4
Weiss, 2015, Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study., Drug Alcohol Depend, 150, 112, 10.1016/j.drugalcdep.2015.02.030
Larochelle, 2018, Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study., Ann Intern Med, 169, 137, 10.7326/M17-3107
Abraham, 2019, County-level access to opioid use disorder medications in Medicare Part D (2010-2015)., Health Serv Res, 54, 390, 10.1111/hesr.2019.54.issue-2
Andrilla, 2019, Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update., J Rural Health, 35, 108, 10.1111/jrh.2019.35.issue-1
Mojtabai, 2019, Medication treatment for opioid use disorders in substance use treatment facilities., Health Aff (Millwood), 38, 14, 10.1377/hlthaff.2018.05162
Jones, 2015, National and state treatment need and capacity for opioid agonist medication-assisted treatment., Am J Public Health, 105, e55, 10.2105/AJPH.2015.302664
Hadland, 2017, Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014., JAMA Pediatr, 171, 747, 10.1001/jamapediatrics.2017.0745
Morgan, 2018, Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population., J Subst Abuse Treat, 85, 90, 10.1016/j.jsat.2017.07.001
Wollschlaeger, 2017, Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse., J Opioid Manag, 13, 207, 10.5055/jom.2017.0389
Morgan, 2019, Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort., Drug Alcohol Depend, 200, 34, 10.1016/j.drugalcdep.2019.02.031
Berger, 2009, Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report, part I., Value Health, 12, 1044, 10.1111/j.1524-4733.2009.00600.x
Quan, 2005, Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data., Med Care, 43, 1130, 10.1097/01.mlr.0000182534.19832.83
Sees, 2000, Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial., JAMA, 283, 1303, 10.1001/jama.283.10.1303
Weiss, 2011, Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial., Arch Gen Psychiatry, 68, 1238, 10.1001/archgenpsychiatry.2011.121
Fiellin, 2014, Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial., JAMA Intern Med, 174, 1947, 10.1001/jamainternmed.2014.5302
Mofizul Islam, 2013, Defining a service for people who use drugs as ‘low-threshold’: what should be the criteria?, Int J Drug Policy, 24, 220, 10.1016/j.drugpo.2013.03.005
Edland-Gryt, 2013, Thresholds in a low-threshold setting: an empirical study of barriers in a centre for people with drug problems and mental health disorders., Int J Drug Policy, 24, 257, 10.1016/j.drugpo.2012.08.002
Schwartz, 2017, Patient-centered methadone treatment: a randomized clinical trial., Addiction, 112, 454, 10.1111/add.13622
Andrews, 2019, Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs., Am J Public Health, 109, 434, 10.2105/AJPH.2018.304856
Clark, 2014, The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence., Health Serv Res, 49, 1964, 10.1111/1475-6773.12201
Lee, 2018, Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial., Lancet, 391, 309, 10.1016/S0140-6736(17)32812-X
Siannis, 2005, Sensitivity analysis for informative censoring in parametric survival models., Biostatistics, 6, 77, 10.1093/biostatistics/kxh019
OptumLabs, 2019
The National Academies of Science, Engineering, and Medicine. Medications for opioid use disorder save lives. March 20, 2019. http://www.nationalacademies.org/hmd/Reports/2019/medications-for-opioid-use-disorder-save-lives.aspx. Accessed March 26, 2019.